Poseida earnings beat by 0.16, revenue topped estimates
| PSTX Stock | USD 9.51 0.06 0.63% |
Slightly above 54% of Poseida Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Poseida Therapeutics suggests that some traders are interested. Poseida Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Poseida Therapeutics' earnings reports, geopolitical events, and overall market trends.
Poseida |
Poseida earnings beat by 0.16, revenue topped estimates
Read at investing.com
 |
Poseida Therapeutics Fundamental Analysis
We analyze Poseida Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Poseida Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Poseida Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
Poseida Therapeutics is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Poseida Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Poseida Therapeutics stock to make a market-neutral strategy. Peer analysis of Poseida Therapeutics could also be used in its relative valuation, which is a method of valuing Poseida Therapeutics by comparing valuation metrics with similar companies.
Peers
Poseida Therapeutics Related Equities
| RVPH | Reviva Pharmaceuticals | 18.87 | ||||
| PHVS | Pharvaris | 6.07 | ||||
| CUE | Cue Biopharma | 3.64 | ||||
| ANTX | AN2 Therapeutics | 2.65 | ||||
| GBIO | Generation Bio | 0.79 | ||||
| MOLN | Molecular Partners | 0.36 | ||||
| CYTK | Cytokinetics | 0.30 | ||||
| MLYS | Mineralys Therapeutics, | 1.45 | ||||
| RVMD | Revolution Medicines | 1.82 | ||||
| STOK | Stoke Therapeutics | 2.11 | ||||
| PLRX | Pliant Therapeutics | 2.20 | ||||
| DYN | Dyne Therapeutics | 3.04 | ||||
| PASG | Passage Bio | 3.80 | ||||
| IPSC | Century Therapeutics | 4.08 | ||||
| LTRN | Lantern Pharma | 4.10 | ||||
| PEPG | PepGen | 5.84 | ||||
| INAB | In8bio | 8.82 |
Additional Tools for Poseida Stock Analysis
When running Poseida Therapeutics' price analysis, check to measure Poseida Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Poseida Therapeutics is operating at the current time. Most of Poseida Therapeutics' value examination focuses on studying past and present price action to predict the probability of Poseida Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Poseida Therapeutics' price. Additionally, you may evaluate how the addition of Poseida Therapeutics to your portfolios can decrease your overall portfolio volatility.